Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT
Buy
Sell